



MRD Testing Implementation Roadmap for Blood Cancers: Pre-Assessment

Thank you for taking the Pre-Assessment for the Measurable Residual Disease (MRD) Testing Implementation Roadmap for Blood Cancers.

Before you begin this pre-assessment, we encourage you to review and discuss it with the core team members for your initiative. This pre-assessment can be used to help guide your thinking as you prepare to implement MRD testing for adult patients with blood cancers.

This pre-assessment will take approximately 5 minutes to complete. **Please be sure to [submit your responses electronically](#).**

Data collected as part of this pre-assessment will help ACCC learn about MRD testing for blood cancers in cancer programs across the country and will inform improvements to the MRD Testing Implementation Roadmap. Data may be presented (aggregated and de-identified) in ACCC publications.

1. Please provide the following information:
 - Project Champion Name & Credentials: _____
 - Project Champion Title: _____
 - Project Champion Email Address: _____
 - What is the name of your organization? (No abbreviations please.)

2. Indicate the category that best describes your cancer program (select only one):
 - Community Cancer Program
 - Academic/NCI Cancer Program
 - Private/Physician Practice
 - Veterans Affairs Cancer Program
 - Other (please specify): _____

3. Approximately how many new and existing adult patients with blood cancers did your organization treat in the last year?
 - AML _____
 - B-cell ALL _____
 - CLL _____
 - Multiple Myeloma _____
 - Other _____

4. Does your organization currently conduct MRD testing in clinical practice for adult blood cancers?
- Yes
 - No (*if no, please go to question 7*)
5. Approximately what percentage of your adult patients with blood cancers currently undergo MRD testing?
- AML _____
 - B-cell ALL _____
 - CLL _____
 - Multiple Myeloma _____
 - Other _____
6. Please briefly describe when/under what circumstances your organization conducts MRD testing for adult patients with blood cancers?

7. Please indicate your level of agreement with the following statements.

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
Our organization has a multidisciplinary team committed to planning and implementing MRD testing for adult patients with blood cancers.					
Our organization's clinical and support staff understand MRD testing methods for adult patients with blood cancers.					
Our organization's clinical and support staff understand the benefits of MRD testing for adult patients with blood cancers.					
Our organization has integrated MRD testing into our clinical information systems (e.g., EMR) and clinical workflows.					